Trial Profile
Randomized, Controlled Study of the Safety and Efficacy of D-CIK Immune Cell Combined With Chemotherapy for Non-Small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dendritic cell activated cytokine-induced killer cells-Shenzhen Hornetcorn (Primary) ; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Shenzhen Hornetcorn Biotechnology
- 23 May 2016 Status changed from not yet recruiting to recruiting.
- 03 Feb 2016 New trial record